Fig. 3

Expression of myoD and somite border effects in the different morphants. (A) Wild-type expression of myoD, (B) in her1 morphants (0.6 mM; 2 experiments, n = 40, 95% show segmental myoD expression, which is slightly more diffuse in anterior somites), (C) in her13.2 morphants (0.6 mM; 2 experiments, n = 38, all embryos show segmental myoD expression) and (D) a full disruption of the myoD pattern in her1/her13.2 morphants (0.6 mM her1^Mo + 0.6 mM her13.2^Mo; 2 experiments, n = 57, 96.49% affected). Somite border disruption in (E) bea^tm98/deltaC mutants (van Eeden et al., 1996 and Jülich et al., 2005b), (F) her13.2^Mo injections in bea^tm98/deltaC mutant background (0.6 mM; 2 experiments, n = 65, all embryos show bea phenotype), (G) Su(H) morphants (0.6 mM; 1 experiment, n = 40, 95% affected, showing the Su(H)^Mo phenotype (Sieger et al., 2003)) and (H) Su(H)/her13.2 double morphants (0.6 mM Su(H)^Mo + 0.6 mM her13.2^Mo; 2 experiments, n = 52, 96.15% show Su(H)^Mo phenotype). No enhanced effects could be observed in panels (F) and (H) when her13.2 morpholino was additionally injected compared to the single bea^tm98 mutant (E) or Su(H) morphant situation (G), respectively. (A–D) 8–10 somite stage embryos, flat mounted embryos, anterior to the top. (E–H) Whole-mount embryos, lateral view, anterior to the left. Stars in panels (E–H) mark the position of the somite borders.